You are here
Bracco Diagnostics Inc. Launches Web-Based Educational Resource on Gadolinium Retention
MONROE TOWNSHIP, N.J., July 1, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced it has launched www.stabilitycounts.com, a source of some of the latest peer-reviewed data and case studies focused on the evolving science around gadolinium retention.
Gadolinium-based contrast agents (GBCAs) have revolutionized magnetic resonance imaging (MRI), and, according to the American College of Radiology, provide crucial, life-saving medical information. Recently, some patients have expressed concern about gadolinium retention and this can cause fear and confusion. Importantly, there are no known adverse clinical consequences associated with gadolinium retention in the brain as recognized by the Food and Drug Administration (FDA) based on the available data.1,2 Nevertheless, some patients have refused to receive GBCAs when undergoing MRI's, even when it could provide healthcare professionals with valuable information for diagnoses.
"Bracco prides itself on making science and research easily accessible to everyone in radiology," said Vittorio Puppo, President and CEO of Bracco Diagnostics Inc. "This resource will further educate customers and arm them with timely and accurate data about gadolinium retention, so they are empowered to use GBCAs when recommended to enhance the diagnostic effectiveness of MRI, and ultimately improve patient care."
When evaluating gadolinium retention, experts agree that tissue sampling studies with inductively coupled plasma mass spectrometry (ICP-MS) provide superior sensitivity versus T1 signal intensity analysis.3 This new website details the three latest comparative, peer-reviewed studies using this technique, to help clarify some scientific aspects around the issue of gadolinium retention. In addition, users can download a paper from a leading neurological institute that details their experience in dealing with this issue.
To visit the site and learn more about this important issue, click here www.stabilitycounts.com
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.
Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.
The company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, Europe and Japan operating through the Joint Venture Bracco-Eisai Co. Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made in order to achieve top quality, compliant and sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China, and Germany.
Bracco Imaging is an innovative Research and Development (R&D) structure with an efficient process-oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centers located in Italy, Switzerland, and the USA.
To learn more about Bracco Imaging, visit www.braccoimaging.com.
1. ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.3.2018. Accessed January 2019. 2. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. FDA website. https://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed December 19, 2018. 3. McDonald RJ, Levine D, Weinreb J, et al. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology. 2018;289(2):517-534.
Bracco Diagnostics Inc. Media Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/bracco-diagnostics-inc-launches-web-based-educational-resource-on-gadolinium-retention-300878468.html
SOURCE Bracco Diagnostics Inc.